Leukemia and Lymphoma

A recent review summarized the current landscape of Bruton tyrosine kinase (BTK) inhibitors in both hematological cancers and inflammatory disorders.

A Swedish population-based study adds to data suggesting men have a higher risk of lymphoma and likely higher mortality.

The annual report notes that progress in reducing cancer mortality is uneven among populations, with minority groups not seeing the same benefits from therapeutic advances. Cancers related to obesity are also on the rise.

A recent study showed that receiving Supplemental Nutrition Assistance Program benefits was not enough to address food insecurity among families whose children were fighting acute lymphoblastic leukemia.

The National Comprehensive Cancer Network recommendations come as the FDA weighs an indication in chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL) for zanubrutinib.

The findings, which contradict prior North American studies, suggest that the incidence rate of the rare cancer continues to increase in the United States.

A retrospective study found that adolescents and young adults (AYA) receiving tyrosine kinase inhibitors (TKI) therapy for chronic-phase chronic myeloid leukemia (CML) had similar prognoses to older patients despite also showing higher tumor burden at diagnosis.

Offering an effective, tolerable, and chemotherapy-free option for patients with chronic lymphocytic leukemia (CLL), Bruton’s tyrosine kinase (BTK) inhibitors have drastically changed the disease’s landscape.

Three approaches—prophylactic immunoglobin, antibiotics, and vaccinations—were investigated for their effectiveness at infection prevention in 3 hematological malignancies.

There are some similarities among various value-based payment programs for cancer care, but they are not identical, said Susan Escudier, MD, FACP, vice president, value-based care and quality programs, Texas Oncology.

The study found that patients with Hodgkin lymphoma (HL) were at an increased risk of any mental health disorder, which was associated with worse long-term outcomes.

The findings can have important implications for shared decision-making between providers and their patients, as well as for future trials of treatments for the disease.

The findings, coming from the phase 3 SEQUOIA study, found that the next-generation, selective Bruton tyrosine kinase inhibitor had superior efficacy versus chemoimmunotherapy and demonstrated an acceptable safety profile among 600 older patients with comorbidities.

Cardiovascular disease (CVD) has, over time, becoming the leading cause of death for patients with early-stage classic Hodgkin lymphoma (cHL), surpassing the risk of death from cHL and other cancers.

Even though the Oncology Care Model (OCM) ended on June 30, 2022, there are some improvements that practices should continue implementing, said Susan Escudier, MD, FACP, vice president of value-based care and quality programs, Texas Oncology.

Researchers of this new study found that treatment with venetoclax may be able to restore activation and proliferation of these cells, suggesting their plasticity can be leveraged for autologous T-cell–based treatments.

Researchers have found that resistance to the BCL2 inhibitor was driven by methylation and epigenetic silencing of PUMA.

A recent review explored current palliative care practices for patients with hematologic cancers compared with solid tumor cancers.

Recent research used incidence and mortality data from the GLOBOCAN 2020 database to gain insight into worldwide patterns of non-Hodgkin lymphoma in 2020.

Anita Kumar, MD, medical oncologist with Memorial Sloan Kettering Cancer Center, led a session at the 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO), on New Directions in Mantle Cell Lymphoma.

Increased diversity in clinical trials remains an unmet need, and in the new SEQUOIA trial, the majority of patients being White males meant researchers could not do a subgroup analysis looking at outcomes for specific races, age groups or genders, said Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Research Center.

A recent meta-analysis aimed to clarify the relationship between parental age and solid tumor pediatric cancers, but more studies are necessary to overcome the limitations of available research.

Finding therapeutic targets for acute myeloid leukemia (AML) has proven challenging, but a set of immune-regulating molecules may hold promise as biomarkers and targets.

A novel prognostic model based on N 6-methyladenosine-associated long non-coding RNAs demonstrated accuracy in determining high- and low-risk disease, suggesting the associated risk value may have potential as a novel biomarker.

Whole-exome sequencing of a family with early-onset cancers found a novel variant in programmed cell death 1 ligand 2 that could potentially indicate germline predisposition to lymphoma.

Tisagenlecleucel (tisa-cel) was approved to treat adults with relapsed or refractory (R/R) follicular lymphoma. This is the third indication for the therapy since it became the first FDA-approved chimeric antigen receptor T-cell therapy in 2017.

Patients being treated for acute myeloid leukemia (AML) who are diagnosed with COVID-19 may be best served by chemotherapy delay until after COVID-19 has run its course.

A recent study identified TIGIT as a marker of chimeric antigen receptor (CAR) T-cell exhaustion and found it to improve CAR T-cell therapy efficacy in preclinical models.

While 5-year survival in adolescent and young adult leukemia has improved in recent decades, this patient population still faces increased long-term mortality compared with the general public.

Significant progress has led to improved survival in patients with HIV/AIDS, but lymphoma remains a leading cause of morbidity and mortality in this patient population.